Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

Corporate Breaking News

Home : Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

Jan 13 2022	Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key...


Source:https://www.prnewswire.com:443/news-releases/ascletis-announces-first-patient-dosed-in-the-phase-ii-clinical-trial-of-fasn-inhibitor-asc40-for-treatment-of-moderate-to-severe-acne-301460288.html

Related News
» Real Time Bidding Market to grow by USD 16.52 bn \| ABB Ltd. and Adobe Inc. Among Key Vendors \| Technavio » Household Cleaning Products Market Records 4.37% Y-O-Y Growth Rate in 2021 \| Church and Dwight Co. Inc. and Colgate-Palmolive Co. Among Key Vendors\| Technavio